

**Iowa Medicaid Pharmaceutical and Therapeutics Committee
Minutes**

Date: December 9, 2005

Chair: Michael A. Flaum, M.D.

Time: 9:35 a.m. to 2:15 p.m.

Location: Iowa State Capitol, Room 116, Des Moines, Iowa

Committee Members Present: Bruce Alexander, R.Ph., Pharm. D., BCPP; Bradley J. Archer, M.D.; Michael A. Flaum, M.D.; Carole A. Frier, D.O.; Hayley L. Harvey, DDS, MS; Matthew Osterhaus, R.Ph.; Susan Purcell, R.Ph, CGP; and Priscilla Ruhe, M.D.

Committee Members Absent: Mary Winegardner, PA-C, MPAS

Iowa DHS Staff Present: Susan Parker, Pharm. D., Pharmacy Consultant

Iowa DHS Staff Absent: Brad Horn, Attorney General's Office

Iowa Medicaid Enterprise (IME) Staff Present: Thomas Kline, D.O., Iowa Medicaid Medical Director; Tim Clifford, M.D.; John Grotton, R.Ph.; Sandy Pranger, R.Ph.; and Julie Bueno, R.Ph.

Dr. Flaum called the meeting to order.

- I. Committee members, DHS staff, and IME staff introduced themselves.
- II. Dr. Clifford said there was no reason to go to closed session for financial discussion on the Recommended Drug List. Dr. Flaum commented on the Recommended Drug List. Dr. Clifford then reviewed the Recommended Drug List, where there were three changes. The three recommended changes in the RDL were to add to the preferred drug Eskalith under the Lithium category, to add Focalin XR under the Stimulants – Methylphenidate category, and to add the generic drug Kogenate under the Antihemophilic Agents category. The Committee discussed Clozaril, Clozapine, the classification system, and Medicare Part D. Dr. Flaum made a motion to accept the Recommended Drug List and change brand name Clozaril to non-preferred and Clozapine to preferred and grandfather existing brand name Clozaril users. Dr. Ruhe seconded the motion. All were in favor with none opposing or abstaining.

- III. Matthew Osterhaus made a motion to go to closed session. Dr. Harvey seconded the motion. A roll call vote was taken and all were in favor with none opposing or abstaining.

Open session reconvened at 11:08 a.m.

- IV. Dr. Flaum explained the mental illness agenda item. He read the legislative request and then reviewed the subcommittee's report. The Committee discussed the options as presented in the subcommittee's report.

The Committee took a 55-minute lunch break.

- V. The Committee resumed their discussion of options as presented in the Subcommittee's report. Bruce Alexander made a motion to move forward with the second generation of anti-psychotics, to investigate corroborative efforts with other states and efforts in the bidding process, and that category B1, B2, and C2 be recommended for adoption. Dr. Flaum asked Bruce Alexander to repeat his motion for clarification. Bruce asked Sandy Pranger to read back his motion, which she did. Dr. Flaum asked for more clarification on the motion. The Committee discussed the motion. Bruce Alexander rephrased his motion to include the second generation antipsychotics as the representative class for the A2 recommendation. Matthew Osterhaus seconded the motion but to say not before July 1, 2006. All were in favor except Dr. Flaum, who opposed. None abstained. Mary Winegardner was absent. Dr. Flaum will amend the report draft and he will send to the Committee members for review. A teleconference will be set up for December 22, 2005, to review the final report.

- VI. Dr. Flaum made a motion for the meeting to be adjourned and Susan Purcell seconded it. All were in favor with none opposing or abstaining.

The meeting adjourned at 2:15 p.m. The next scheduled meeting will be March 9, 2006.